Blog

DISCERN™ Receives First-in-Category PLA Codes SYNAPS Dx (SDx) is pleased to announce that DISCERN™ is the first AD test to earn Proprietary Laboratory Analyses (PLA) Codes 206U and 207U.  DISCERN™ is the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative …

SYNAPS Dx Completes $10 Million Series A Investment Accelerates Commercialization of DISCERN™: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease There are approximately 500,000 new cases of dementia each year in the United States, with about 2 million patients in years 0-3 of the disease at any given time. With the emergence of new drugs …

SYNAPS Dx Joins Maryland Tech Council A new independent study finds that Maryland has built one of the nation’s strongest life sciences industries, which directly employs more than 54,000 workers. A division of MTC, Maryland Life Sciences, recently commissioned a report from the globally recognized Milken Institute that also identifies new opportunities for the public and private sectors to …

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), announces that DISCERN™, the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative …